UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021-12, Vol.27 (12), p.1700-1705

2021

Volltextzugriff (PDF)

Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

Blood, 2018-11, Vol.132 (Supplement 1), p.399-399

2018

Volltextzugriff (PDF)

P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL

HemaSphere, 2023-08, Vol.7 (S3), p.e1847498-n/a

2023

Volltextzugriff (PDF)

P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19‐CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL

HemaSphere, 2023-08, Vol.7 (S3), p.e19857ae-n/a

2023

Volltextzugriff (PDF)

P1134: BISPECIFIC ANTI‐CD20/19 CAR‐T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY‐II‐USA STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e07109dc-n/a

2023

Volltextzugriff (PDF)

Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype

Blood, 2023-11, Vol.142 (Supplement 1), p.2075-2075

2023

Volltextzugriff (PDF)

Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia

Blood, 2020-10, Vol.136 (17), p.1946-1955

2020

Volltextzugriff (PDF)

Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis

Blood, 2022-11, Vol.140 (Supplement 1), p.10818-10819

2022

Volltextzugriff (PDF)

Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience

Blood, 2023-11, Vol.142 (Supplement 1), p.2172-2172

2023

Volltextzugriff (PDF)

Improving Diversity, Equity, and Inclusion Education in Hematology/Oncology Training

Blood, 2022-11, Vol.140 (Supplement 1), p.5029-5030

2022

Volltextzugriff (PDF)

Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma

Leukemia & lymphoma, 2020-12, Vol.61 (14), p.3387-3394

2020

Volltextzugriff (PDF)

Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Blood, 2023-11, Vol.142 (Supplement 1), p.4497-4497

2023

Volltextzugriff (PDF)

Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy

Blood, 2023-11, Vol.142 (Supplement 1), p.68-68

2023

Volltextzugriff (PDF)

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Blood, 2023-11, Vol.142 (Supplement 1), p.2132-2132

2023

Volltextzugriff (PDF)

Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas

Leukemia & lymphoma, 2020-10, Vol.61 (12), p.2955-2961

2020

Volltextzugriff (PDF)

Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion

American journal of health-system pharmacy, 2021-06, Vol.78 (12), p.1112-1117

2021

Volltextzugriff (PDF)

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Blood, 2022-11, Vol.140 (Supplement 1), p.10410-10412

2022

Volltextzugriff (PDF)

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.774-776

2022

Volltextzugriff (PDF)

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma

Gastroenterology research and practice, 2011-01, Vol.2011 (2011), p.1-3

2011

Volltextzugriff (PDF)

Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation

Blood, 2019-11, Vol.134 (Supplement_1), p.4055-4055

2019

Volltextzugriff (PDF)

Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2024-09

2024

Volltextzugriff (PDF)

Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7575-7575

2022

Volltextzugriff (PDF)

Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas

Blood, 2020-11, Vol.136 (Supplement 1), p.21-22

2020

Volltextzugriff (PDF)

1 – 25 von 105

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(96)
Mit Volltextzugriff
(91)

Publikationsform

Artikel
(104)
Berichte
(1)

Sprache

Englisch
(105)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(24)
Science & Technology
(24)
Hematology
(16)
Humans
(15)
Oncology
(13)
Male
(6)
Aged
(5)
Female
(5)
Follicular Lymphoma
(5)
Lymphoma
(5)
Middle Aged
(5)
Adult
(4)
Poster Abstracts
(4)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
B-Cell Lymphoma
(3)
Chemotherapy
(3)
Cost-Benefit Analysis
(3)
Immunology
(3)
Lymphoma, Follicular - Drug Therapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib

Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL

P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19‐CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL

P1134: BISPECIFIC ANTI‐CD20/19 CAR‐T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY‐II‐USA STUDY

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma

Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype

Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia

Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis

Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience

Improving Diversity, Equity, and Inclusion Education in Hematology/Oncology Training

Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma

Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas

Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma

Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation

Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma

Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies

Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas

Suchergebnisse filtern